QCI Interpret's latest software update comes with several new features, including a new workflow for comprehensive cancer panels and greater variant coverage for labs using the GRCh38 reference genome

We are pleased to announce that the Summer 2022 Release of QCI Interpret, QIAGEN’s decision support software platform for the annotation, classification, and reporting of actionable alterations from next-generation sequencing (NGS) data in clinical genomic laboratories, is now available. Expanding on the software’s current capabilities, the QCI Interpret Summer 2022 Release brings new workflows, variant content and functionality improvements.

QCI Interpret Summer 2022 Release highlights

• New Homologous Recombination Deficiency (HRD) workflow for comprehensive cancer panels that enable reporting of targeted therapies and clinical trials associated with this emerging tumor biomarker.
• GRCh38-aligned gnomAD v3.1.2 allele frequency data and greater variant coverage is now available to laboratories using the GRCh38 reference genome.
• Improved test management workflow support to help with the coordination of cases within large teams.
• Improved test creation process to optimize the sample selection process for labs running large multi-sample tests.
• ACMG SF 3.1 compliance to provide full support for review of variants in genes from the ACMG v3.1 secondary findings update, including curated bibliography coverage of all variants.

About QCI Interpret

QCI Interpret is a clinical decision support software platform for the annotation, classification, and reporting of actionable alterations from NGS data for oncology and hereditary disease applications. Using augmented molecular intelligence and expertly curated content from the QIAGEN Knowledge Base, QCI Interpret applies a rules-based approach to automatically compute pathogenicity classifications (Pathogenic to Benign) and actionability classifications (Tier 1 to 4) for each alteration according to professional guidelines from ACMG/AMP and AMP/ASCO/CAP, respectively.

Pathogenicity and actionability classifications in QCI Interpret are accompanied by clear visibility into the criteria and evidence supporting the classifications. This workflow starts with a variant call format (VCF) file, so it is compatible with the output from any NGS platform. The final report includes the alterations, interpretations, and references specified throughout the assessment process, which has customizable automation capabilities allowing for streamlined clinical decision support workflows. 

Learn more about QCI Interpret for Oncology here.

Learn more about QCI Interpret for Hereditary Diseases here.

The industry-leading NGS variant interpretation and reporting software now includes a new Clinical Validity feature, Dynamic Candidate Disease Identification, NICE guidelines and more

We are pleased to announce that the latest QIAGEN Clinical Insight (QCI) Interpret software release is now available. Expanding on the software’s current capabilities, the update adds new features and guidelines to enhance the interpretation and reporting of genomic variants.

Release Highlights

Clinical Validity

Immediately determine and filter to genes implicated in hereditary diseases that are most relevant to report with Strong or Definitive Clinical Validity. With this new features, users can quickly review clinical validity statements that summarize the evidence supporting the strength of a gene-disease relationship. Gene-disease relationships include those determined by the ClinGen Gene Curation Working Group and are extended to cover all gene-diseases via computing clinical validity based on the ClinGen classification guidelines using the expert-curated and integrated evidence in the QIAGEN Knowledge Base.

Dynamic Candidate Disease Identification from Symptoms

Interactively add and remove symptoms (and diseases) in hereditary workflows at anytime. With this new feature, users can rapidly adjust symptoms if more case information becomes available. The ranking of candidate diseases for variants in the Phenotype Driven Ranking (PDR) view is dynamically updated based on the updated symptoms.

Phenotype Network Diagram

Review curated evidence supporting each candidate disease for a case in the hereditary workflow with the Phenotype Network—a new feature that provides a summary of the gene-disease clinical validity and a visual diagram of the paths via QIAGEN Knowledge Base relationships from symptoms provided for a case to a candidate disease. This enables users to quickly and interactively review relationship-specific supporting evidence, including source citations.

National Institute for Health and Care Excellence (NICE) Guidelines for Oncology

The NICE Guidelines for Oncology are now available for clinical reporting in QCI Interpret and QCI Interpret One. QIAGEN’s expert guideline curation provides the most up-to-date evidence-based guidance from NICE to support treatment selection for patients. NICE guideline recommendations are also used to support the computed AMP/ASCO/CAP variant classification to ensure relevant variants are indicated for review.

For information about the latest release, including the full release notes, please contact your QIAGEN Digital Insights account manager or customer support at ts-bioinformatics@qiagen.com.

Want to learn more about QCI Interpret?

• Learn more about QCI Interpret here.
• View a QCI Interpret sample report for inherited diseases here.
• View a QCI Interpret sample report for hereditary cancer here.

We also invite you to watch our on-demand webinar, "Overcoming Challenges of Copy Number Variant (CNV) Interpretation," where our experts provide a virtual demonstration of QCI Interpret, showing how users can quickly evaluate CNVs and compute their pathogenicity using the new ACMG/ClinGen guidelines.

Ready for a free, personalized demonstration of QCI Intepret?

Visit our QCI Interpret webpage to request a complimentary demonstration.

Discover more about the latest QCI update and how the platform simplifies and accelerates NGS variant analysis, interpretation, and reporting

We are pleased to announce a minor update to QIAGEN Clinical Insight (QCI), a clinical informatics platform for streamlined NGS variant analysis, interpretation, and reporting of oncology and inherited disease tests. The update adds new features, functionalities, and improvements, further enhancing QCI's ease-of-use, performance, and responsiveness.

New QCI features and functionalities

• Performance improvements – Updates to the user-interface that limit the amount of processing needed to render the application. This has resulted in significant improvements in performance and responsiveness. In addition, users will now be informed about expected processing times.
• New Genetic Analysis filter – A Genetic Analysis filter that enables users to filter (exclude/include) variants of specific genotypes.
• Display CADD and HGMD annotations in Variants View – For hereditary workflow users can now bring CADD and HGMD annotations to the Variants View for quick lookups and sorting of CADD scores. Plus for HGMD users, now included are annotations link outs to the variant’s HGMD mutation detail page.
• Improved sample uploader – Users can load new samples without waiting for an existing sample to complete processing.
• Support for .PED file – Family/trio analysis can have sample relationships described via .PED file format. This metadata describes family relationships similar to how the existing JSON format supports relationships in prior versions.
• New Application Programming Interface (API) endpoint – New API for developers to integrate existing LIMS/informatics system with QCI Interpret Translational to automate the upload of samples.

Explore the QCI portfolio

• QCI Interpret Translational - A NGS variant assessment software solution that enables rapid, evidence-powered variant annotation, filtering, and triage for human exome, genome, and large cohort sequencing data.
• QCI Interpret - Clinical decision support software for molecular diagnostic labs that enables faster turnaround times, higher confidence reporting, and test menu expansion for oncology and inherited diseases.
• QCI Interpret One  - Clinical decision support software integrated with professional variant interpretation services that enables molecular diagnostic labs to perform rapid, evidence-based reporting of oncology NGS tests at scale.
• QCI Precision Insights - A professional clinical interpretation service for oncology NGS tests that translates molecular data specific to each patient into clinical insights and therapeutic options.

We are excited to announce the general availability of the Fall 2020 Release of QIAGEN Clinical Insight (QCI) Interpret. This new release brings the following new features:

• We’ve added new variant triaging capabilities into QCI Interpret to allow filtering based on sequencing and upstream artifacts (Confidence Filter), population frequency (Common Variants Filter), pathogenicity (Predicted Deleterious Filter), and biological relevance (Biological Context).
• A new workflow has been introduced to allow test creation from sample inventory, as well as supporting legacy sample upload and analysis.
• Inventoried somatic samples can be used for multi-sample somatic analysis (ex. time-based samples).
• We’ve made changes to the variant list page to better cluster relevant genes/variants, as well as updated/added new view settings.
• This release also features the ability to export the annotations associated with filtered variants in the variants table.
• A new addition is the MITOMAP content for better annotating mitochondrial variants.
• QCI Interpret One is now available in Europe containing EU-specific content.

To learn more about the new features and functionalities of QCI Interpret, please attend our free webinar on November 10 at 11 AM EST. Register here.

If you are a current QCI customer and have questions about the new release, please contact support at ts-bioinformatics@qiagen.com.